HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

MengSi Liu Selected Research

FKB327

1/2021Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


MengSi Liu Research Topics

Disease

2Hematologic Neoplasms (Hematological Malignancy)
01/2021 - 01/2021
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2022
1cell-associated neurotoxicity
01/2021
1Cytokine Release Syndrome
01/2021
1Rheumatoid Arthritis
01/2021
1Leukemia
01/2021
1Lymphoma (Lymphomas)
01/2021
1Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2021

Drug/Important Bio-Agent (IBA)

3axicabtagene ciloleucelIBA
01/2021 - 01/2021
3tisagenlecleucelIBA
01/2021 - 01/2021
2Chimeric Antigen ReceptorsIBA
01/2022 - 01/2021
1Adalimumab (Humira)FDA Link
01/2021
1Tumor Necrosis Factor InhibitorsIBA
01/2021
1Biological ProductsIBA
01/2021
1Biosimilar PharmaceuticalsIBA
01/2021
1ABP 501IBA
01/2021
1GP2017IBA
01/2021
1PF-06410293IBA
01/2021
1BI 695501IBA
01/2021
1FKB327IBA
01/2021

Therapy/Procedure

2Therapeutics
01/2022 - 01/2021